Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma.
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre-Bénite, France University Claude Bernard Lyon 1,Lyon, France.
Clémentine
C
Sarkozy
John Francis
JF
Seymour
Christophe
C
Ferme
Dolores
D
Caballero
Hervé
H
Ghesquieres
Sirpa
S
Leppa
Richard
R
Delarue
Lars Moller
LM
Pedersen
Christiane
C
Mounier
Maria
M
Gomes Da Silva
Catherine
C
Chassagne-Clement
Marie
M
Maerevoet
Gilles
G
Salles
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D008224:Lymphoma, Follicular / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D009360:Neoplastic Cells, Circulating / Q000378:metabolism; D011379:Prognosis; D016016:Proportional Hazards Models; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab